Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia

The data that support the findings of this study are available from the corresponding author, [KAD], upon reasonable request.

Authors

Institutions

Publication Details

Journal
Haemophilia
Published
2026-03-27
DOI
https://doi.org/10.1111/hae.70273
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia

Sanjay Ahuja, Kyle Davis, Amy Shapiro
Haemophilia
Hemophilia Treatment and Research
article

Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia

Sanjay Ahuja, Kyle Davis, Amy Shapiro
article en

Abstract

The data that support the findings of this study are available from the corresponding author, [KAD], upon reasonable request.

Haemophilia
Innovative Clinical Research (US)
Zero hunger
Openalex Percentile: Top 5%
Hemophilia Treatment and Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Milds Matter—Feasibility of Emicizumab Prophylaxis in Mild Hemophilia — Sanjay Ahuja, Kyle Davis, et al. · Haemophilia (2026) | TGRS Research Map | TGRS